Epidemiologie - France Portal | Health Databases

Home

Catalogue

Catalogue
ARCHIVES

Covid-19

Resources

Lexicon
Legal notices

Useful links

General links
Covid-19 links

Login in to your account

Email address Password

You do not have an account yet ? Sign up !

You have forgotten your password ?

Portail Epidémiologique

ITMO public health Aviesan

Aviesan

Archives

Search with one or more keywords

All records French records only English records only

This page gives you access to all the studies carried out by French researchers, identified on Covid-19.

To view other resources related to Covid-19, click here.

xml

Export to XML

Please choose the format :

pdf

Export to PDF

Which version do you want to export ?

Download full content

Download light content

csv

Export to CSV

What sections do you want to export ?

Métadonnées
Identification
General Aspects
Scientific investigator(s) (Contact)
Collaborations
Funding
Governance of the database
Additional contact
Type of database
Database objective
Population type
Dates
Size of the database
Data
Procedures
Promotion
Access
Select all | Invert selection | No selection

ARCHIVES : 309 forms

Sorting of results :

PhotoGRAF - Facteurs de risque du glaucome primitif à angle ouvert chez les sujets atteints d'hypertonie oculaire

Head : Troy Sylvie, Pfizer

Version 2

31

Last update : 01/01/2018

ARCHIVE

PhotoGRAF - Facteurs de risque du glaucome primitif à angle ouvert chez les sujets atteints d'hypertonie oculaire

Head : Troy Sylvie, Pfizer

Main objective

Main:
- Evaluate the differences between the cases afflicted with primary open-angle glaucoma (POAG) and the controls afflicted with isolated ocular hypertension (OHT) concerning the potential risk factors, including sociodemographic factors, systemic diseases and treatments in progress, family antecedents of glaucoma, the duration of the disease, the factors linked to the eye, nutritional factors and the exposure to environmental neurotoxic compounds.
Secondary:
- Derive a predictive function by using the significant risk factors, in such a way as to assist ophthalmologists in classifying patients having a hypertonia with a high risk of developing glaucoma

Inclusion criteria

For the cases:
- Male or female aged 40 years or older;
- Patients with a diagnosed POAG, confirmed by a structural and function degradation;
- Patients for whom a IOP > 21 mm Hg was recorded at one time in the evolution of the disease.

For the controls
- Male or female paired with the age of the case (± 2 years);
- Patients having an IOP > 21 mm Hg on the day of the examination and/or a hypotonisant treatment;
- Patients with a visual acuity with optimal correction higher than 5/10;
- Patients with no anomaly in the visual field characteristic of glaucoma.

Last update : 01/01/2018

DISCOVER - Screening for extracoronary atherothrombotic localizations after an acute coronary syndrome and clinical management of patients

Head : Herrmann Marie-Annick, Bristol-Myers Squibb
Schmidely Nathalie, Bristol-Myers Squibb

Version 1

32

Last update : 09/05/2017

ARCHIVE

DISCOVER - Screening for extracoronary atherothrombotic localizations after an acute coronary syndrome and clinical management of patients

Head : Herrmann Marie-Annick, Bristol-Myers Squibb
Schmidely Nathalie, Bristol-Myers Squibb

Main objective

Evaluate the frequency of uninvestigated and investigated patients in the detection of extra-coronary atherothrombotic locations in a population of patients having an history of ACS in the year preceding the selection visit and followed by office based cardiologists.

Inclusion criteria

M/F, >=18 years, examined in consultation by an office based cardiologist, with an history of ACS with or without ST-segment elevation in the 12 months preceding the selection

Last update : 09/05/2017

SISTOLA - Observational usage and effectiveness of candesartan in heart failure treatment in France

Head : Thomas-Delcourt Florence, AstraZeneca

Version 2

33

Last update : 01/01/2020

ARCHIVE

SISTOLA - Observational usage and effectiveness of candesartan in heart failure treatment in France

Head : Thomas-Delcourt Florence, AstraZeneca

Main objective

To describe the way candesartan is used in heart failure treatment in France (treatment initiation and follow-up) treatment discontinuation occurences and reasons why and patients clinical evolution

Inclusion criteria

Patients starting or who have recently started (less than 30 days) a treatment with candesartan for heart failure

Last update : 01/01/2020

- Cross-sectional study on the labour force in Lorraine: relationship between lifestyle/living conditions, work and workplace accidents

Head : Falissard Bruno , Inserm U1018 - Centre de Recherche en Épidémiologie et Santé des Populations Équipe: Genre, Santé sexuelle et Reproductive
Chau Nearkasen, U 669

Version 1

34

Last update : 10/20/2017

ARCHIVE

- Cross-sectional study on the labour force in Lorraine: relationship between lifestyle/living conditions, work and workplace accidents

Head : Falissard Bruno , Inserm U1018 - Centre de Recherche en Épidémiologie et Santé des Populations Équipe: Genre, Santé sexuelle et Reproductive
Chau Nearkasen, U 669

Main objective

To study the relationship between work, lifestyle/life conditions and workplace accidents

Inclusion criteria

Random selection from the Lorraine labour force

Last update : 10/20/2017

YZATIS - Evaluation et évolution de la prise en charge thérapeutique à moyen terme des patients séropositifs pour le VIH-1 traités avec une combinaison antirétrovirale incluant Atazanavir

Head : Bennai Yacia, Bristol-Myers Squibb
Schmidely Nathalie, Bristol-Myers Squibb

Version 1

35

Last update : 09/05/2017

ARCHIVE

YZATIS - Evaluation et évolution de la prise en charge thérapeutique à moyen terme des patients séropositifs pour le VIH-1 traités avec une combinaison antirétrovirale incluant Atazanavir

Head : Bennai Yacia, Bristol-Myers Squibb
Schmidely Nathalie, Bristol-Myers Squibb

Main objective

Describe the arrangements for caring for patients treated by a combination of treatments including ATAZANAVIR according to the grounds for introducing the treatment (virological failure of the previous treatment or other)

Inclusion criteria

M or F, aged 18 years or older, seropositive for HIV-1, treated via a combination of ARV treatments including ATV for which the main reason for introduction of the current treatment was: - virological failure of the previous treatment OR
- another reason.

Last update : 09/05/2017

APTOR - Prospective observational study of patients with acute coronary syndrome managed by PCI and antiplatelet treatment: Antiplatelet Treatment Observational Registry

Head : Médecin pharmacoépidémiologiste

Version 2

36

Last update : 01/01/2018

ARCHIVE

APTOR - Prospective observational study of patients with acute coronary syndrome managed by PCI and antiplatelet treatment: Antiplatelet Treatment Observational Registry

Head : Médecin pharmacoépidémiologiste

Main objective

Primary objective: evaluate the use of healthcare resources and cost in the 12 months following a percutaneous coronary intervention (PCI) combined with antiplatelet treatment in patients with acute coronary syndrome.
Secondary objectives: quality of life and clinical evolution.

Inclusion criteria

Be diagnosed with acute coronary syndrome,
- treatment with percutaneous coronary intervention in routine care;
- start or continue antiplatelet treatment.

Last update : 01/01/2018

Previous
1
2
3
4
5
6
7
8
9
10
11
12
...
52
Next

Please wait...

ABOUT

Help about your workspace

CATALOG

RESOURCES

USEFUL LINKS

This site complies with the HONcode standard for trustworthy health information:
verify here.

8 rue de la Croix Jarry

75013 Paris

Phone : +33 1 44 23 67 47

portail-epidemiologie@inserm.fr

Partners - FAQ - Contact - Site map - Legal notices - Administration - Updated on December 15 2020 - Version 4.10.05

XXX

View Edit Create here